
AKTS Stock Forecast & Price Target
AKTS Analyst Ratings
Bulls say
Aktis Oncology is attractive fundamentally because it combines two differentiated clinical-stage 225Ac miniprotein radioconjugates, AKY-1189 and AKY-2519, against validated but under-served targets with broad solid-tumor expression, creating multiple shots on goal across UC, TNBC, NSCLC, mCRPC, SCLC, and CRC. Its early imaging, dosimetry, and preclinical data support a potentially wide therapeutic index—highlighted by low normal-tissue exposure, robust tumor uptake, and tumor-growth inhibition as high as 92%—while $517.3MM in 2Q26 cash is estimated to fund operations into 2029, reducing near-term financing pressure. The company also benefits from strategic validation through the Eli Lilly collaboration, multiple 225Ac supply agreements, and an internal GMP facility expected online in 2H26, all of which strengthen execution and future commercial scalability.
Bears say
Aktis Oncology is exposed to significant clinical and execution risk because its valuation depends heavily on AKY-1189 and AKY-2519 proving differentiated activity and tolerability, and any poorer-than-expected results would undermine the investment case. The company also faces meaningful competitive pressure if rival products outperform, while isotope supply or manufacturing constraints could delay development and restrict scalability for its targeted radiopharmaceutical programs. Given its clinical-stage profile, single operating focus on R&D, and reliance on collaboration agreement revenue, the business lacks diversified operating support and remains vulnerable to reimbursement and pipeline setbacks.
This aggregate rating is based on analysts' research of Aktis Oncology Inc and is not a guaranteed prediction by Public.com or investment advice.
AKTS Analyst Forecast & Price Prediction
Start investing in AKTS
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Aktis Oncology Inc (AKTS) Forecast
AKTS Analyst Forecast & Price Prediction
Start investing in AKTS
Order type
Buy in
Order amount
Est. shares
0 shares